Clinical Trial Update: Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema [Phase 2, Phase 3]

View source ↗

Summary

Extension study of oral PHA-022121 for acute treatment of angioedema attacks in hereditary angioedema. The trial is in Phase 2/Phase 3 and is currently enrollin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• PHA-022121

Snippet

Sponsor: Pharvaris Netherlands B.V. | Conditions: Hereditary Angioedema, Hereditary Angioedema Type I | Phase 2, Phase 3 | Status: ENROLLING_BY_INVITATION